Glaukos (NYSE:GKOS) Stock Rating Raised to Strong-Buy at Zacks Research

Glaukos (NYSE:GKOS) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

Other analysts have also issued research reports about the stock. Citigroup lifted their price objective on shares of Glaukos from $225.00 to $247.00 and gave the stock a “buy” rating in a research report on Thursday. Truist Financial raised their price target on shares of Glaukos from $215.00 to $255.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC upped their price target on Glaukos from $201.00 to $251.00 and gave the company a “buy” rating in a research report on Thursday. UBS Group started coverage on shares of Glaukos in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $150.00 target price for the company. Finally, Wall Street Zen raised shares of Glaukos from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and an average target price of $216.71.

Glaukos Trading Up 32.7%

NYSE:GKOS opened at $240.81 on Wednesday. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. Glaukos has a twelve month low of $80.90 and a twelve month high of $243.71. The company has a fifty day moving average of $172.26 and a 200-day moving average of $140.51.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.98% and a negative net margin of 24.60%. The company had revenue of $211.03 million for the quarter, compared to analyst estimates of $168.04 million. During the same period in the prior year, the firm earned ($0.16) earnings per share. Glaukos’s revenue for the quarter was up 58.0% on a year-over-year basis. On average, analysts predict that Glaukos will post -0.32 earnings per share for the current fiscal year.

Insider Activity

In other Glaukos news, Director Gilbert Kliman sold 2,500 shares of Glaukos stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the transaction, the director directly owned 37,406 shares of the company’s stock, valued at $7,107,140. The trade was a 6.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Joseph E. Gilliam sold 60,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the completion of the transaction, the chief operating officer owned 72,588 shares in the company, valued at $13,046,967.12. The trade was a 45.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 82,500 shares of company stock valued at $14,862,000. 5.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Allworth Financial LP purchased a new stake in Glaukos during the 2nd quarter valued at about $28,000. CoreCap Advisors LLC purchased a new position in Glaukos in the 3rd quarter worth approximately $33,000. Fortitude Family Office LLC bought a new position in Glaukos in the 3rd quarter valued at approximately $36,000. Parallel Advisors LLC lifted its position in Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 226 shares in the last quarter. Finally, IFP Advisors Inc boosted its stake in Glaukos by 523.4% during the 2nd quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 246 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Q3 results far exceeded expectations: Third-quarter revenue rose 58% year over year to approximately $211 million, well above the roughly $168 million analyst estimate. The company reported adjusted EPS of $0.47 versus consensus expectations for a loss of about $0.10–$0.12, compared with a $0.16 loss a year earlier. Glaukos Stock Charges Higher on Q3 Earnings Surprise
• Positive Sentiment: Profitability improved: Glaukos reported approximately $2 million in GAAP net income, or $0.03 per diluted share, marking a swing from a year-earlier loss. Operating cash flow was $14.8 million, and the company ended the quarter with $162.3 million in cash. Glaukos Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Sales outlook was raised: Management increased its 2026 revenue guidance to $775 million–$785 million from $680 million–$700 million and introduced a preliminary 2027 sales target of $1 billion. Investors viewed the outlook as evidence that iDose TR and Epioxa can sustain strong growth. Glaukos Sets $1 Billion 2027 Sales Goal
• Positive Sentiment: Analysts raised targets: JPMorgan lifted its target to $240 and retained an Overweight rating, while Needham raised its target to $251 with a Buy rating. BTIG, Stifel and Wells Fargo also increased their targets and maintained positive ratings. JPMorgan Analyst Recommendation
• Neutral Sentiment: Valuation has become demanding: The stock was trading near its 52-week high and above several newly raised analyst targets, including those from Wells Fargo, BTIG and Stifel, potentially limiting near-term upside despite bullish ratings.
• Negative Sentiment: Insider selling remains a risk signal: Data provided shows 32 open-market insider sales and no purchases over the past six months. The company also remains dependent on continued execution to meet its ambitious 2027 target.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.